Immunic AG

Industry / private company


Location: Planegg-Martinsried, Germany (DE) DE

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Orally bioavailable RORγ/DHODH dual host-targeting small molecules with broad-spectrum antiviral activity (2024) Herrmann A, Gege C, Wangen C, Wagner S, Kögler M, Cordsmeier A, Irrgang P, et al. Journal article Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity (2024) Gege C, Hahn F, Wangen C, Häge S, Herrmann A, Uhlig N, Eberlein V, et al. Journal article Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels (2024) Wangen C, Raithel A, Tillmanns J, Gege C, Herrmann A, Vitt D, Kohlhof H, et al. Journal article IMU-838, a small molecule DHODH inhibitor in phase II clinical trial for multiple sclerosis, shows potent Anti-EBV activity in cell-culture-based systems: Potential additional benefits in multiple sclerosis treatment (2021) Marschall M, Peelen E, Müller R, Wangen C, Wagner S, Muehler A, Groeppel M, et al. Conference contribution Methodological development of a multi-readout assay for the assessment of antiviral drugs against sars-cov-2 (2021) Hahn F, Häge S, Herrmann A, Wangen C, Kicuntod J, Jungnickl D, Tillmanns J, et al. Journal article